Testing a new malaria vaccine by mosquito bite
Part of Infections clinical trials.
This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old and in good health.
- You have never had malaria or a malaria vaccine, and haven't recently visited a malaria-risk area.
- Your blood type is O negative.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
- You are willing to have blood samples taken and stored for research, and to avoid donating blood for 6 months after the study ends.
- You are not taking certain medications that could interfere with the study (like blood thinners or steroids).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.
This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.